MODERNA vs BNTX Comparison: AI Score, Valuation, Performance and Upside
Compare Moderna's broader mRNA-pipeline diversification beyond COVID vaccines against BioNTech's oncology-focused pipeline and Pfizer partnership.
Use this Moderna vs BioNTech comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
MODERNA and BNTX are closely matched — they split the tracked metrics evenly.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
| Metric | MODERNA | BNTX |
|---|---|---|
| AI scorei | N/A | 58.7 |
| AI ranki | N/A | #199 |
| Latest closei | N/A | $96.06 |
| 1M returni | N/A | -15.08% |
| 6M returni | N/A | +7.61% |
| 1Y returni | N/A | -0.26% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | MODERNA | BNTX |
|---|---|---|
| 1Y ago | N/A | $9.97K (-0.3%) started 2025-09-18 |
| 5Y ago | N/A | $2.91K (-70.9%) started 2021-09-20 |
| 10Y ago | N/A | $69.26K (+592.6%) started 2019-10-10 |
Hypothetical — past performance does not guarantee future results.
| Metric | MODERNA | BNTX |
|---|---|---|
| Market capi | N/A | $24.13B |
| Trailing P/Ei | N/A | N/A |
| Forward P/Ei | N/A | -19.55 |
| Price/Salesi | N/A | 9.11 |
| EV/Revenuei | N/A | 4.14 |
| Analyst targeti | N/A | $118.25 |
| Target upsidei | N/A | +23.10% |
| Metric | MODERNA | BNTX |
|---|---|---|
| Revenue growthi | N/A | -59.50% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | N/A | -9.42% |
| Operating margini | N/A | -806.63% |
| Profit margini | N/A | -63.64% |
| ROIC proxyi | N/A | -9.30% |
| Return on equityi | N/A | -9.30% |
| Dividend yieldi | N/A | 0.00% |
| Payout ratioi | N/A | 0.00% |
| Dividend growth streaki | N/A | No increase yet |
| Betai | N/A | 1.29 |
| Debt/equityi | N/A | 1.78 |
| Current ratioi | N/A | 7.85 |
| Quick ratioi | N/A | 7.03 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | MODERNA | BNTX |
|---|---|---|---|
| 1Y | Growthi | N/A | -0.26% |
| CAGRi | N/A | -0.26% | |
| Volatilityi | N/A | 45.80% | |
| Sharpe ratioi | N/A | 0.12 | |
| Sortino ratioi | N/A | 0.18 | |
| Max drawdowni | N/A | 29.71% | |
| Current drawdowni | N/A | 19.51% | |
| Avg drawdowni | N/A | 14.49% | |
| Ulcer Indexi | N/A | 16.88% | |
| Max daily dropi | N/A | 17.88% | |
| Max wkly dropi | N/A | 16.74% | |
| 5Y | Growthi | N/A | -71.29% |
| CAGRi | N/A | -22.11% | |
| Volatilityi | N/A | 52.96% | |
| Sharpe ratioi | N/A | -0.29 | |
| Sortino ratioi | N/A | -0.42 | |
| Max drawdowni | N/A | 78.10% | |
| Current drawdowni | N/A | 73.15% | |
| Avg drawdowni | N/A | 65.03% | |
| Ulcer Indexi | N/A | 66.33% | |
| Max daily dropi | N/A | 20.92% | |
| Max wkly dropi | N/A | 29.13% | |
| 10Y | Growthi | N/A | +583.51% |
| CAGRi | N/A | +31.91% | |
| Volatilityi | N/A | 75.42% | |
| Sharpe ratioi | N/A | 0.67 | |
| Sortino ratioi | N/A | 1.10 | |
| Max drawdowni | N/A | 82.25% | |
| Current drawdowni | N/A | 78.24% | |
| Avg drawdowni | N/A | 57.17% | |
| Ulcer Indexi | N/A | 62.88% | |
| Max daily dropi | N/A | 35.54% | |
| Max wkly dropi | N/A | 48.70% |
| Category | MODERNA | BNTX |
|---|---|---|
| Company | MODERNA | BNTX |
| Sector | N/A | N/A |
| Industry | N/A | Biotechnology |
| Core business | N/A | BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.